The SMFM 2026 Global Congress in Utrecht brought together maternal health professionals and researchers from around the world. For Lepzi, it was an opportunity to share its research and hear how clinicians are thinking about access to pre-eclampsia assess

A major moment at the congress was the launch of the World Health Organization’s Global Roadmap for Hypertensive Disorders of Pregnancy, 2026–2035 and Beyond. The roadmap calls for coordinated progress in research and innovation, clinical guidance, access to health products, implementation, and advocacy. It also highlights the need for more equitable access to quality care, particularly in low- and middle-income countries.

That global ambition connected with a practical theme in conversations at the congress: getting useful information to healthcare professionals in time to inform care. Clinicians and researchers discussed how local laboratory capacity, referral pathways, cost, and reimbursement can affect access to biomarker testing. Attendees also showed interest in point-of-care approaches for remote and resource-limited settings, where access to laboratory services may be more challenging.